Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Menstrual blood-derived mesenchymal stem cells (MenSCs) is an investigational cell therapy developed by S-Evans Biosciences for the treatment of type 1 diabetes mellitus. These mesenchymal stem cells are isolated from menstrual blood, providing a non-invasive and ethically uncomplicated source of multipotent cells characterized by high proliferation rates and the ability to differentiate into various cell lineages. The therapy is hypothesized to function through immunomodulation and the promotion of endogenous pancreatic progenitor cell differentiation, thereby improving glycemic control and potentially regenerating or preserving beta-cell function. It has been evaluated in Phase 1/2 clinical trials involving intravenous or intra-arterial (pancreatic artery) administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on menstrual blood-derived mesenchymal stem cells (S-Evans Biosciences).